APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibody-drug Conjugates for Tumors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antibody-drug Conjugates for Tumors Market Outlook and Growth Opportunities 2026

26 December 2025195 pages

Choose your research edition.

Industry ResearchAntibody-drug Conjugates for Tumors Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody-drug Conjugates for Tumors Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Antibody-drug Conjugates for Tumors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody-drug Conjugates for Tumors Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody-drug Conjugates for Tumors Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Antibody-drug Conjugates for Tumors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antibody-drug Conjugates for Tumors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antibody-drug Conjugates for Tumors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antibody-drug Conjugates for Tumors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antibody-drug Conjugates for Tumors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antibody-drug Conjugates for Tumors market include Takeda, RemeGen, Roche（Genentech）, Rakuten Medical, Gilead Sciences, Pfizer（Seagen), GSK, Daiichi Sankyo and AbbVie(ImmunoGen), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antibody-drug Conjugates for Tumors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibody-drug Conjugates for Tumors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibody-drug Conjugates for Tumors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antibody-drug Conjugates for Tumors market size, projected growth trends, production technologies, key applications, and end-use industries.

Antibody-drug Conjugates for Tumors Segment by Company

Takeda

RemeGen

Roche（Genentech）

Rakuten Medical

Gilead Sciences

Pfizer（Seagen)

GSK

Daiichi Sankyo

AbbVie(ImmunoGen)

AstraZeneca

ADC Therapeutics

Antibody-drug Conjugates for Tumors Segment by Type

DNA Damaging Drugs

Tubulin Inhibitors

Other

Antibody-drug Conjugates for Tumors Segment by Application

Hematological Tumors

Solid Tumors

Antibody-drug Conjugates for Tumors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antibody-drug Conjugates for Tumors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antibody-drug Conjugates for Tumors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antibody-drug Conjugates for Tumors significant trends, drivers, influence factors in global and regions.

6. To analyze Antibody-drug Conjugates for Tumors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-drug Conjugates for Tumors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody-drug Conjugates for Tumors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-drug Conjugates for Tumors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antibody-drug Conjugates for Tumors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antibody-drug Conjugates for Tumors industry.

Chapter 3: Detailed analysis of Antibody-drug Conjugates for Tumors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antibody-drug Conjugates for Tumors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antibody-drug Conjugates for Tumors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antibody-drug Conjugates for Tumors Industry Trends Table 2. Antibody-drug Conjugates for Tumors Industry Drivers Table 3. Antibody-drug Conjugates for Tumors Industry Opportunities and Challenges Table 4. Antibody-drug Conjugates for Tumors Industry Restraints Table 5. Global Antibody-drug Conjugates for Tumors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antibody-drug Conjugates for Tumors Revenue Share by Company (2021-2026) Table 7. Global Antibody-drug Conjugates for Tumors Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Antibody-drug Conjugates for Tumors Sales Volume Share by Company (2021-2026) Table 9. Global Antibody-drug Conjugates for Tumors Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Antibody-drug Conjugates for Tumors Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antibody-drug Conjugates for Tumors Key Company Manufacturing Base & Headquarters Table 12. Global Antibody-drug Conjugates for Tumors Company, Product Type & Application Table 13. Global Antibody-drug Conjugates for Tumors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antibody-drug Conjugates for Tumors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of DNA Damaging Drugs Table 18. Significant Companies of Tubulin Inhibitors Table 19. Significant Companies of Other Table 20. Global Antibody-drug Conjugates for Tumors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Antibody-drug Conjugates for Tumors Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Antibody-drug Conjugates for Tumors Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Antibody-drug Conjugates for Tumors Sales Volume Share by Type (2021-2026) Table 24. Global Antibody-drug Conjugates for Tumors Sales Volume Share by Type (2027-2032) Table 25. Global Antibody-drug Conjugates for Tumors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antibody-drug Conjugates for Tumors Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Antibody-drug Conjugates for Tumors Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Antibody-drug Conjugates for Tumors Sales Value Share by Type (2021-2026) Table 29. Global Antibody-drug Conjugates for Tumors Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hematological Tumors Table 31. Significant Companies of Solid Tumors Table 32. Global Antibody-drug Conjugates for Tumors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Antibody-drug Conjugates for Tumors Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Antibody-drug Conjugates for Tumors Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Antibody-drug Conjugates for Tumors Sales Volume Share by Application (2021-2026) Table 36. Global Antibody-drug Conjugates for Tumors Sales Volume Share by Application (2027-2032) Table 37. Global Antibody-drug Conjugates for Tumors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Antibody-drug Conjugates for Tumors Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Antibody-drug Conjugates for Tumors Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Antibody-drug Conjugates for Tumors Sales Value Share by Application (2021-2026) Table 41. Global Antibody-drug Conjugates for Tumors Sales Value Share by Application (2027-2032) Table 42. Global Antibody-drug Conjugates for Tumors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Antibody-drug Conjugates for Tumors Sales by Region (2021-2026) & (K Units) Table 44. Global Antibody-drug Conjugates for Tumors Sales Market Share by Region (2021-2026) Table 45. Global Antibody-drug Conjugates for Tumors Sales by Region (2027-2032) & (K Units) Table 46. Global Antibody-drug Conjugates for Tumors Sales Market Share by Region (2027-2032) Table 47. Global Antibody-drug Conjugates for Tumors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Antibody-drug Conjugates for Tumors Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Antibody-drug Conjugates for Tumors Sales Value Share by Region (2021-2026) Table 50. Global Antibody-drug Conjugates for Tumors Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Antibody-drug Conjugates for Tumors Sales Value Share by Region (2027-2032) Table 52. Global Antibody-drug Conjugates for Tumors Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Antibody-drug Conjugates for Tumors Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Antibody-drug Conjugates for Tumors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Antibody-drug Conjugates for Tumors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Antibody-drug Conjugates for Tumors Sales by Country (2021-2026) & (K Units) Table 57. Global Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021-2026) Table 58. Global Antibody-drug Conjugates for Tumors Sales by Country (2027-2032) & (K Units) Table 59. Global Antibody-drug Conjugates for Tumors Sales Market Share by Country (2027-2032) Table 60. Global Antibody-drug Conjugates for Tumors Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Antibody-drug Conjugates for Tumors Sales Value Market Share by Country (2021-2026) Table 62. Global Antibody-drug Conjugates for Tumors Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Antibody-drug Conjugates for Tumors Sales Value Market Share by Country (2027-2032) Table 64. Takeda Company Information Table 65. Takeda Business Overview Table 66. Takeda Antibody-drug Conjugates for Tumors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Takeda Antibody-drug Conjugates for Tumors Product Portfolio Table 68. Takeda Recent Development Table 69. RemeGen Company Information Table 70. RemeGen Business Overview Table 71. RemeGen Antibody-drug Conjugates for Tumors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. RemeGen Antibody-drug Conjugates for Tumors Product Portfolio Table 73. RemeGen Recent Development Table 74. Roche（Genentech） Company Information Table 75. Roche（Genentech） Business Overview Table 76. Roche（Genentech） Antibody-drug Conjugates for Tumors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Roche（Genentech） Antibody-drug Conjugates for Tumors Product Portfolio Table 78. Roche（Genentech） Recent Development Table 79. Rakuten Medical Company Information Table 80. Rakuten Medical Business Overview Table 81. Rakuten Medical Antibody-drug Conjugates for Tumors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Rakuten Medical Antibody-drug Conjugates for Tumors Product Portfolio Table 83. Rakuten Medical Recent Development Table 84. Gilead Sciences Company Information Table 85. Gilead Sciences Business Overview Table 86. Gilead Sciences Antibody-drug Conjugates for Tumors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Gilead Sciences Antibody-drug Conjugates for Tumors Product Portfolio Table 88. Gilead Sciences Recent Development Table 89. Pfizer（Seagen) Company Information Table 90. Pfizer（Seagen) Business Overview Table 91. Pfizer（Seagen) Antibody-drug Conjugates for Tumors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Pfizer（Seagen) Antibody-drug Conjugates for Tumors Product Portfolio Table 93. Pfizer（Seagen) Recent Development Table 94. GSK Company Information Table 95. GSK Business Overview Table 96. GSK Antibody-drug Conjugates for Tumors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. GSK Antibody-drug Conjugates for Tumors Product Portfolio Table 98. GSK Recent Development Table 99. Daiichi Sankyo Company Information Table 100. Daiichi Sankyo Business Overview Table 101. Daiichi Sankyo Antibody-drug Conjugates for Tumors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Daiichi Sankyo Antibody-drug Conjugates for Tumors Product Portfolio Table 103. Daiichi Sankyo Recent Development Table 104. AbbVie(ImmunoGen) Company Information Table 105. AbbVie(ImmunoGen) Business Overview Table 106. AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Product Portfolio Table 108. AbbVie(ImmunoGen) Recent Development Table 109. AstraZeneca Company Information Table 110. AstraZeneca Business Overview Table 111. AstraZeneca Antibody-drug Conjugates for Tumors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. AstraZeneca Antibody-drug Conjugates for Tumors Product Portfolio Table 113. AstraZeneca Recent Development Table 114. ADC Therapeutics Company Information Table 115. ADC Therapeutics Business Overview Table 116. ADC Therapeutics Antibody-drug Conjugates for Tumors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. ADC Therapeutics Antibody-drug Conjugates for Tumors Product Portfolio Table 118. ADC Therapeutics Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Antibody-drug Conjugates for Tumors Distributors List Table 122. Antibody-drug Conjugates for Tumors Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Antibody-drug Conjugates for Tumors Product Image Figure 2. Global Antibody-drug Conjugates for Tumors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody-drug Conjugates for Tumors Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antibody-drug Conjugates for Tumors Sales (2021-2032) & (K Units) Figure 5. Global Antibody-drug Conjugates for Tumors Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Antibody-drug Conjugates for Tumors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. DNA Damaging Drugs Image Figure 10. Tubulin Inhibitors Image Figure 11. Other Image Figure 12. Global Antibody-drug Conjugates for Tumors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Antibody-drug Conjugates for Tumors Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Antibody-drug Conjugates for Tumors Sales Volume Share by Type (2021-2032) Figure 15. Global Antibody-drug Conjugates for Tumors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Antibody-drug Conjugates for Tumors Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Antibody-drug Conjugates for Tumors Sales Value Share by Type (2021-2032) Figure 18. Hematological Tumors Image Figure 19. Solid Tumors Image Figure 20. Global Antibody-drug Conjugates for Tumors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Antibody-drug Conjugates for Tumors Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Antibody-drug Conjugates for Tumors Sales Volume Share by Application (2021-2032) Figure 23. Global Antibody-drug Conjugates for Tumors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Antibody-drug Conjugates for Tumors Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Antibody-drug Conjugates for Tumors Sales Value Share by Application (2021-2032) Figure 26. Global Antibody-drug Conjugates for Tumors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Antibody-drug Conjugates for Tumors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Antibody-drug Conjugates for Tumors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Antibody-drug Conjugates for Tumors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Antibody-drug Conjugates for Tumors Sales Value (2021-2032) & (US$ Million) Figure 31. North America Antibody-drug Conjugates for Tumors Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Antibody-drug Conjugates for Tumors Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Antibody-drug Conjugates for Tumors Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Antibody-drug Conjugates for Tumors Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Antibody-drug Conjugates for Tumors Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Antibody-drug Conjugates for Tumors Sales Value (2021-2032) & (US$ Million) Figure 37. South America Antibody-drug Conjugates for Tumors Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Antibody-drug Conjugates for Tumors Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Antibody-drug Conjugates for Tumors Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Antibody-drug Conjugates for Tumors Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Antibody-drug Conjugates for Tumors Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • DNA Damaging Drugs
  • Tubulin Inhibitors
  • Other
Applications
  • Hematological Tumors
  • Solid Tumors
Companies covered
  • Takeda
  • RemeGen
  • Roche（Genentech）
  • Rakuten Medical
  • Gilead Sciences
  • Pfizer（Seagen)
  • GSK
  • Daiichi Sankyo
  • AbbVie(ImmunoGen)
  • AstraZeneca
  • ADC Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antibody-drug Conjugates for Tumors Sales Value (2021-2032)
  4. 1.2.2 Global Antibody-drug Conjugates for Tumors Sales Volume (2021-2032)
  5. 1.2.3 Global Antibody-drug Conjugates for Tumors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antibody-drug Conjugates for Tumors Market Dynamics
  1. 2.1 Antibody-drug Conjugates for Tumors Industry Trends
  2. 2.2 Antibody-drug Conjugates for Tumors Industry Drivers
  3. 2.3 Antibody-drug Conjugates for Tumors Industry Opportunities and Challenges
  4. 2.4 Antibody-drug Conjugates for Tumors Industry Restraints
3 Antibody-drug Conjugates for Tumors Market by Company
  1. 3.1 Global Antibody-drug Conjugates for Tumors Company Revenue Ranking in 2025
  2. 3.2 Global Antibody-drug Conjugates for Tumors Revenue by Company (2021-2026)
  3. 3.3 Global Antibody-drug Conjugates for Tumors Sales Volume by Company (2021-2026)
  4. 3.4 Global Antibody-drug Conjugates for Tumors Average Price by Company (2021-2026)
  5. 3.5 Global Antibody-drug Conjugates for Tumors Company Ranking (2024-2026)
  6. 3.6 Global Antibody-drug Conjugates for Tumors Company Manufacturing Base and Headquarters
  7. 3.7 Global Antibody-drug Conjugates for Tumors Company Product Type and Application
  8. 3.8 Global Antibody-drug Conjugates for Tumors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antibody-drug Conjugates for Tumors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antibody-drug Conjugates for Tumors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antibody-drug Conjugates for Tumors Market by Type
  1. 4.1 Antibody-drug Conjugates for Tumors Type Introduction
  2. 4.1.1 DNA Damaging Drugs
  3. 4.1.2 Tubulin Inhibitors
  4. 4.1.3 Other
  5. 4.2 Global Antibody-drug Conjugates for Tumors Sales Volume by Type
  6. 4.2.1 Global Antibody-drug Conjugates for Tumors Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antibody-drug Conjugates for Tumors Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Antibody-drug Conjugates for Tumors Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Antibody-drug Conjugates for Tumors Sales Value by Type
  10. 4.3.1 Global Antibody-drug Conjugates for Tumors Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Antibody-drug Conjugates for Tumors Sales Value by Type (2021-2032)
  12. 4.3.3 Global Antibody-drug Conjugates for Tumors Sales Value Share by Type (2021-2032)
5 Antibody-drug Conjugates for Tumors Market by Application
  1. 5.1 Antibody-drug Conjugates for Tumors Application Introduction
  2. 5.1.1 Hematological Tumors
  3. 5.1.2 Solid Tumors
  4. 5.2 Global Antibody-drug Conjugates for Tumors Sales Volume by Application
  5. 5.2.1 Global Antibody-drug Conjugates for Tumors Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antibody-drug Conjugates for Tumors Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Antibody-drug Conjugates for Tumors Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Antibody-drug Conjugates for Tumors Sales Value by Application
  9. 5.3.1 Global Antibody-drug Conjugates for Tumors Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Antibody-drug Conjugates for Tumors Sales Value by Application (2021-2032)
  11. 5.3.3 Global Antibody-drug Conjugates for Tumors Sales Value Share by Application (2021-2032)
6 Antibody-drug Conjugates for Tumors Regional Sales and Value Analysis
  1. 6.1 Global Antibody-drug Conjugates for Tumors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antibody-drug Conjugates for Tumors Sales by Region (2021-2032)
  3. 6.2.1 Global Antibody-drug Conjugates for Tumors Sales by Region: 2021-2026
  4. 6.2.2 Global Antibody-drug Conjugates for Tumors Sales by Region (2027-2032)
  5. 6.3 Global Antibody-drug Conjugates for Tumors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antibody-drug Conjugates for Tumors Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antibody-drug Conjugates for Tumors Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antibody-drug Conjugates for Tumors Sales Value by Region (2027-2032)
  9. 6.5 Global Antibody-drug Conjugates for Tumors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antibody-drug Conjugates for Tumors Sales Value (2021-2032)
  12. 6.6.2 North America Antibody-drug Conjugates for Tumors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antibody-drug Conjugates for Tumors Sales Value (2021-2032)
  15. 6.7.2 Europe Antibody-drug Conjugates for Tumors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antibody-drug Conjugates for Tumors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antibody-drug Conjugates for Tumors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antibody-drug Conjugates for Tumors Sales Value (2021-2032)
  21. 6.9.2 South America Antibody-drug Conjugates for Tumors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antibody-drug Conjugates for Tumors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antibody-drug Conjugates for Tumors Sales Value Share by Country, 2025 VS 2032
7 Antibody-drug Conjugates for Tumors Country-level Sales and Value Analysis
  1. 7.1 Global Antibody-drug Conjugates for Tumors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antibody-drug Conjugates for Tumors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antibody-drug Conjugates for Tumors Sales by Country (2021-2032)
  4. 7.3.1 Global Antibody-drug Conjugates for Tumors Sales by Country (2021-2026)
  5. 7.3.2 Global Antibody-drug Conjugates for Tumors Sales by Country (2027-2032)
  6. 7.4 Global Antibody-drug Conjugates for Tumors Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antibody-drug Conjugates for Tumors Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antibody-drug Conjugates for Tumors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antibody-drug Conjugates for Tumors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antibody-drug Conjugates for Tumors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antibody-drug Conjugates for Tumors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Antibody-drug Conjugates for Tumors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Antibody-drug Conjugates for Tumors Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 RemeGen
  8. 8.2.1 RemeGen Company Information
  9. 8.2.2 RemeGen Business Overview
  10. 8.2.3 RemeGen Antibody-drug Conjugates for Tumors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 RemeGen Antibody-drug Conjugates for Tumors Product Portfolio
  12. 8.2.5 RemeGen Recent Developments
  13. 8.3 Roche（Genentech）
  14. 8.3.1 Roche（Genentech） Company Information
  15. 8.3.2 Roche（Genentech） Business Overview
  16. 8.3.3 Roche（Genentech） Antibody-drug Conjugates for Tumors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Roche（Genentech） Antibody-drug Conjugates for Tumors Product Portfolio
  18. 8.3.5 Roche（Genentech） Recent Developments
  19. 8.4 Rakuten Medical
  20. 8.4.1 Rakuten Medical Company Information
  21. 8.4.2 Rakuten Medical Business Overview
  22. 8.4.3 Rakuten Medical Antibody-drug Conjugates for Tumors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Rakuten Medical Antibody-drug Conjugates for Tumors Product Portfolio
  24. 8.4.5 Rakuten Medical Recent Developments
  25. 8.5 Gilead Sciences
  26. 8.5.1 Gilead Sciences Company Information
  27. 8.5.2 Gilead Sciences Business Overview
  28. 8.5.3 Gilead Sciences Antibody-drug Conjugates for Tumors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Gilead Sciences Antibody-drug Conjugates for Tumors Product Portfolio
  30. 8.5.5 Gilead Sciences Recent Developments
  31. 8.6 Pfizer（Seagen)
  32. 8.6.1 Pfizer（Seagen) Company Information
  33. 8.6.2 Pfizer（Seagen) Business Overview
  34. 8.6.3 Pfizer（Seagen) Antibody-drug Conjugates for Tumors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer（Seagen) Antibody-drug Conjugates for Tumors Product Portfolio
  36. 8.6.5 Pfizer（Seagen) Recent Developments
  37. 8.7 GSK
  38. 8.7.1 GSK Company Information
  39. 8.7.2 GSK Business Overview
  40. 8.7.3 GSK Antibody-drug Conjugates for Tumors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GSK Antibody-drug Conjugates for Tumors Product Portfolio
  42. 8.7.5 GSK Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo Antibody-drug Conjugates for Tumors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo Antibody-drug Conjugates for Tumors Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 AbbVie(ImmunoGen)
  50. 8.9.1 AbbVie(ImmunoGen) Company Information
  51. 8.9.2 AbbVie(ImmunoGen) Business Overview
  52. 8.9.3 AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Product Portfolio
  54. 8.9.5 AbbVie(ImmunoGen) Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Antibody-drug Conjugates for Tumors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Antibody-drug Conjugates for Tumors Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 ADC Therapeutics
  62. 8.11.1 ADC Therapeutics Company Information
  63. 8.11.2 ADC Therapeutics Business Overview
  64. 8.11.3 ADC Therapeutics Antibody-drug Conjugates for Tumors Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 ADC Therapeutics Antibody-drug Conjugates for Tumors Product Portfolio
  66. 8.11.5 ADC Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antibody-drug Conjugates for Tumors Value Chain Analysis
  2. 9.1.1 Antibody-drug Conjugates for Tumors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antibody-drug Conjugates for Tumors Sales Mode & Process
  6. 9.2 Antibody-drug Conjugates for Tumors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antibody-drug Conjugates for Tumors Distributors
  9. 9.2.3 Antibody-drug Conjugates for Tumors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst